Contract Research
Contract Research reports are the public domain output of consultancy projects that are published with the clients permission when the content is of interest to a wide audience.
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible for substantial health and economic burden to health systems and wider society.
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
Tumour-agnostic (TA) therapies represent a paradigm shift in oncology by targeting molecular alterations regardless of tumour histology.
Achieving Accelerated Patient Access to Cancer Care in Europe
3 November 2025
OHE developed the Accelerated Patient Access to Cancer Care in Europe (APACE) framework through a structured, multidisciplinary stakeholder engagement process.
The value of cell and gene therapies to the UK economy
20 October 2025
Cell and gene therapies (CGTs) are moving rapidly from specialist trials to routine care: more than thirty products are already licensed worldwide and over two thousand are in clinical development.
The broader economic benefits of COVID-19 vaccination
13 October 2025
Extending COVID-19 vaccination eligibility to working-age adults could nearly triple the benefits to national economies.
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually…
Altering the trajectory of HIV in Europe
22 May 2025
Despite substantial medical advancements that have transformed HIV into a manageable chronic condition for individuals, the epidemic remains a pressing public health concern in Europe.
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.